MyFinsight
Home
Blog
About
Increase in accounts
payable and accrued...
$65,347K
(-8.16%↓ Y/Y)
Proceeds from maturity of
held-to-maturity securities
$17,750K
(-86.32%↓ Y/Y)
Proceeds from exercise of
options
$85K
(-81.24%↓ Y/Y)
Stock-based compensation
$27,875K
(-11.04%↓ Y/Y)
Decrease (increase) in
other current assets
-$13,573K
(-237.28%↓ Y/Y)
Net income
$7,781K
(-76.60%↓ Y/Y)
Increase in deferred
revenue
$7,298K
(278.72%↑ Y/Y)
Deferred income taxes
$708K
Change in fair value of
notes payable
-$524K
(-251.68%↓ Y/Y)
Noncash change in lease
liability and right of use...
$441K
(-50.17%↓ Y/Y)
Amortization of debt issuance
costs
$247K
(-59.38%↓ Y/Y)
Depreciation and
amortization
$53K
(152.38%↑ Y/Y)
Amortization of leasehold
interest
$43K
(-54.26%↓ Y/Y)
Net cash provided by
(used in) operating...
$39,263K
(284.52%↑ Y/Y)
Net cash used in
investing activities
$1,030K
(106.09%↑ Y/Y)
Net cash provided by
(used in) financing...
$85K
(100.68%↑ Y/Y)
Canceled cashflow
$84,627K
Canceled cashflow
$16,720K
Net increase
(decrease) in cash, cash...
$40,378K
(179.56%↑ Y/Y)
Increase in inventory
$66,824K
(56.46%↑ Y/Y)
Increase in accounts
receivable
$9,519K
(-90.70%↓ Y/Y)
Decrease in income taxes
payable
-$6,133K
Change in fair value of
equity investments
$1,227K
(530.53%↑ Y/Y)
Decrease in lease
liabilities
-$408K
(61.55%↑ Y/Y)
Decrease in other current
liabilities
-$262K
(88.95%↑ Y/Y)
Amortization of premium
(discount) on investment...
$254K
(-90.30%↓ Y/Y)
Investment in
held-to-maturity securities
$16,427K
(-88.70%↓ Y/Y)
Purchases of property,
plant and equipment
$293K
(337.31%↑ Y/Y)
Back
Back
Cash Flow
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)
source: myfinsight.com